Literature DB >> 22495876

Rituximab induced pulmonary fibrosis in a patient with lupus nephritis.

M Rathi1, R Ramachandran, S Gundlapalli, R Agarwal, A Das, V Kumar, H S Kohli, V Jha, V Sakhuja.   

Abstract

We describe a 26-year-old woman who was diagnosed eleven years ago with systemic lupus erythematosus and who had suffered multiple relapses. She presented with class IV lupus nephritis with thrombotic microangiopathy, for which she received three doses of rituximab along with plasmapheresis, with no response, and soon became dialysis dependent. One month after the last dose of rituximab, she presented with dyspnoea and hypoxia. A transbronchial lung biopsy revealed pulmonary fibrosis. A diagnosis of rituximab induced pulmonary fibrosis was made after excluding other causes and she was treated with intravenous methyl prednisolone with which there was marked improvement in symptoms and hypoxemia. This is the first report of rituximab induced pulmonary fibrosis in a patient with lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495876     DOI: 10.1177/0961203312444892

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  1 in total

Review 1.  Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Authors:  Sunad Rangarajan; Morgan L Locy; Tracy R Luckhardt; Victor J Thannickal
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.